Glycolytic Reprogramming in Uterine Fibroids: Genetic, Transcriptomic, Proteomic, and Metabolomic Insights
Genes · 2025
DOI: 10.3390/genes16111268 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Samya El Sayed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Reproductive Sciences and Women's Health Research, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Leiomyoma, Glycolysis, Uterine Neoplasms, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Uterine leiomyomas or fibroids are a common but pernicious benign tumor impacting between 70–80% of women of reproductive age. Despite their high prevalence, the etiology of uterine fibroids is not fully understood. This review aims to highlight the distinct metabolic features that uterine fibroids adopt to meet biosynthetic demands, support proliferation, extracellular matrix production, survival, and fibrosis. Specifically, we posit the role of glycolytic reprogramming—an adaptation in fibrosis across organs (lung, kidney, heart, and liver) as a major contributor to uterine fibroid development. Previous genetic, transcriptomic, proteomic, and metabolic studies have drawn strong links between metabolism and uterine fibroid biology and identified genotype-specific metabolic alterations such as fumarate hydratase (FH) deficiency and mediator of RNA polymerase II transcription (MED12) gene mutations. Studies in non-uterine models have linked glycolysis to ECM production and fibrosis through activation of transforming growth factor-beta (TGF-β) and the canonical Wnt pathway (Wnt/β-catenin) signaling, supporting them as potential key pathways in uterine fibroid pathogenesis via glycolytic reprogramming. Other metabolic regulators, such as hypoxia-inducible factor 1-alpha (HIF-1α), mammalian target of rapamycin (mTOR), and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), may also sustain the fibrotic phenotype through coupling signaling that drives ECM production to metabolic programming. Overall, the proposed metabolic perspective of uterine fibroid pathogenesis invites further exploration of mechanistic investigation in uterine-specific models and therapeutic targeting through larger cohort studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Reproductive Sciences and Women's Health Research, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
- Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
ORCID-Profile: Valentina Vanos, Rachel Michel, Mostafa Borahay
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
El Sayed, S., Pan, A., Vanos, V., Michel, R., & Borahay, M. (2025). Glycolytic Reprogramming in Uterine Fibroids: Genetic, Transcriptomic, Proteomic, and Metabolomic Insights. Genes. https://doi.org/10.3390/genes16111268
Vancouver
El Sayed S, Pan A, Vanos V, Michel R, Borahay M. Glycolytic Reprogramming in Uterine Fibroids: Genetic, Transcriptomic, Proteomic, and Metabolomic Insights. Genes. 2025. doi:10.3390/genes16111268
BibTeX
@article{ElSayed2025,
author = {El Sayed, Samya and Pan, Alvina and Vanos, Valentina and Michel, Rachel and Borahay, Mostafa},
title = {Glycolytic Reprogramming in Uterine Fibroids: Genetic, Transcriptomic, Proteomic, and Metabolomic Insights},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16111268}
}
EUVIMED